1. Introduction {#sec1}
===============

Alzheimer\'s disease is the most common form of neurodegenerative disorders \[[@B1]\] characterized by the formation of extracellular deposits composed of amyloid beta peptide (A*β*) \[[@B2]\] and masses of paired, helically wound protein filaments in the cytoplasm of neuronal cell bodies and neuritic processes called neurofibrillary tangles \[[@B3]\]. These NFTs are formed as a result of hyperphosphorylation of tau protein \[[@B4]\]. The tau proteins are phosphoproteins whose levels of phosphorylation are regulated by tau kinases and phosphatases \[[@B5]\]. Substantial evidence reveals the increased activity of glycogen synthase kinase 3*β* (GSK3*β*) (also known as human tau protein kinase I) during AD. Similarly, P25/cyclin-dependent kinase 5 (Cdk5), dual-specific tyrosine \[Y\] regulated kinase 1A (Dyrk1A), and mitogen-activated protein kinases (MAPK) also possess higher activity in AD brain \[[@B6]\].

Thus, our work focuses on the chosen 10 kinases involved in hyperphosphorylation of tau and elevated responses in AD \[[@B7]\]. Kinase holds a large gene family and these domains are alike in sequence and structure. Developments of discriminating inhibitors are a key task in drug discovery and development, and appreciating the basis of kinase inhibitor selectivity is critical to the design of effective drugs.

GSK3*β* is composed of three domains: an N-terminal domain consisting of a closed *β*-barrel structure, a C-terminal domain containing a "kinase fold" structure, and a small extradomain subsequent to the C-terminal domain. The catalytic site is between the two major domains and has an ATP analogue molecule in its ATPbinding site. The adenine ring is buried in the hydrophobic pocket and interacts specifically with the main-chain atoms of the hinge loop \[[@B8]\]. The structure of GSK3*β* is known to have a catalytically active dimer conformation that progressively phosphorylates substrates with Ser/Thr penta repeats \[[@B9]\]. It is known that the inhibitors compete with the ATP binding sites of GSK3*β* \[[@B10], [@B11]\]. Realizing the need to design the inhibitors for these kinases, with the hope that it could affect the hyperphosphorylation of tau, the investigations have been undertaken. The studies reveal shared conservations across sequences, structural homologies, and ATP binding site geometries across the ten tau kinases. Interestingly, the inhibitor 3-aminopyrrolidine scaffold exhibits high preferential affinity with GSK3*β*. Though the literature on AD indicates overexpression and activity of GSK3*β* during pathogenesis of AD, surprisingly, the PDB does not contain the structural details of GSK3*β* with these specific inhibitors. Consequently, our explorations provide vital clues towards design of novel off-target drugs for AD.

2. Materials and Methods {#sec2}
========================

The analysis of the structures of the 10 tau kinases, along with their respective ligands, was carried out as illustrated in the flow chart ([Figure 1](#fig1){ref-type="fig"}). To begin with, the structures of the 10 tau kinases, along with their respective ligands, were retrieved from the PDB and their details are provided in [Table 1](#tab1){ref-type="table"}. A Phylogenetic tree was generated for the amino acid sequences of 10 tau kinases using CLUSTALW \[[@B12]\] and is illustrated in [Figure 2](#fig2){ref-type="fig"}. The dendrogram reveals that GSK3*β*, CDK5, MAPK such as p38, extracellular signal-regulated kinases 1 & 2 (ERK 1/2), c-Jun N-terminal kinase (JNK), and dual-specificity tyrosine-\[Y\]-phosphorylation-regulated kinase 1A (DYRK1A) are closely related (as in cluster 1); protein kinase A (PKA), protein kinase B (AKT/PKB), and protein kinase C (PKC) form the closely related second cluster. Interestingly, casein kinase 1 delta (CK1d) stands out as an independent taxis, indicating characteristic sequence variations from the group.

To observe the conservation of residues in the ATP binding region, a multiple sequence alignment was carried out amongst the 10 kinases, using the tool MultAlin \[[@B13]\]. The alignment is depicted in [Figure 3(a)](#fig3){ref-type="fig"}, which reveals that the sequences differ significantly at the positions of gate-keeper residues and the surface residues, while they are well conserved at the subsites that interact directly with ATP. The ATP binding amino acids LYS 85 & ASP 200, ASP 133 & VAL 135 and GLU 185 are conserved across these kinases, and lie in the phosphate binding region, adenine binding region and in the sugar binding regions respectively (refer to [Figure 3(b)](#fig3){ref-type="fig"}). Overall sequence identity and similarity amongst the sequences and RMSD between the 3D geometries are highlighted in [Table 2](#tab2){ref-type="table"}. The identity (and similarity) amongst the kinase sequences lies in the broad range of 22.8% (48.1%) and 49% (77.4%). The closest set appears between ERK1/2 and P38, which share the highest identity of 49%, while the least values of 22.8% exist between 2 sets, namely, CK1d and CDK5 and AKT and ERK1/2, respectively. The structural alignment to calculate the RMSD values was carried out using MultiProt \[[@B14]\]. It is interesting to note that the RMSD between all pairs of 10 tau kinases for C*α* atoms range between 1.07 and 1.82 Å (refer to [Table 2](#tab2){ref-type="table"}). Interestingly, these lowest and highest values of RMSD are related to the molecule PKC. However as expected, for the molecule CK1d which stands out in the phylogeny, the identities with all other kinases are less than 30%. Similarly, the RMSD values of all the kinases with CK1d lie in the higher range of 1.57 to 1.76 Å. Further, the structural alignments revealed that the active site occurs between two lobes of kinases showing the conserved overlap of the ATP binding regions. Thus, the RMSD values for the entire ATP binding region amongst the kinases lie between 0.63 and 1.25 Å. However, the RMSD values for the phosphate binding region lie between 0.23 and 0.46 Å, and the nucleotide binding region is in-between 0.16 and 1.25 Å respectively. Hence, docking the binding site of kinases with ATP was attempted to appreciate the nature of interactions. [Table 3](#tab3){ref-type="table"} provides the molecular details and properties of the various inhibitors used in the study. Their relative binding affinities in terms of IC50 and *K* ~*i*~ values are also indicated for each inhibitor ([Table 3](#tab3){ref-type="table"}). The set of chosen inhibitors does contain two small molecules which are deposited in the drug bank, that is, inhibitor 2 (Drug Bank ID DB07794) and inhibitor 5 (Drug Bank ID DB07919). In order to appreciate the structural similarity of these inhibitors with ATP, 3D alignments were carried out across the 7 kinase inhibitors and ATP. The outcome of these structural comparisons revealed that the RMSD between ATP and the 7 ligands lie between 0.37 and 0.67 Å, while the inhibitor-to-inhibitor RMSD values are in the range of 0.32 to 0.67 Å. All the RMSD values are consolidated in [Table 4](#tab4){ref-type="table"}.

The ATP binding site of GSK3*β* spans a long stretch containing 22 residues. [Table 5](#tab5){ref-type="table"} lists the various residues forming the ATP binding pocket and exhibiting favorable interactions with ATP. In order to appreciate the conservation of this ATP binding site across all 10 tau kinases, ATP molecule was docked and all plausible interactions within 6 Å were tabulated. Docking studies were carried out using the Discovery Studio software Version 3.5 (Accelrys Software Inc., USA) and Lead IT tool of FlexX 2.1.2. It is clear from [Table 5](#tab5){ref-type="table"} that G63, A83, K85, E97, D/E133, N186, and D200 form the set of well-conserved residues in the ATP binding pocket and interact with ATP in all the 10 kinases. Though the molecules JNK and ERK1/2 exhibit less number of interactions with ATP, key contacts of conserved residues are indeed present. Residue corresponding to V110 exhibits least number of interactions across kinases. Though the residue corresponding to R141 appears changed in all the kinases, its interactions with ATP, across the receptors, are well conserved.

Our aim to study the efficacies of select inhibitors with GSK3*β* triggered the need to dock these ligands to the key tau kinase GSK3*β*. Identifying the ATP binding site, the molecular docking studies of kinase inhibitors were carried out using the Discovery Studio software Version 3.5 and Lead IT tool of FlexX 2.1.2. GSK3*β* receptor structure was docked to all of the seven ligands to the ATP binding pocket by the rigid receptor-flexible ligand docking competencies of FlexX and the interactions are tabulated in [Table 6](#tab6){ref-type="table"}. The docking examination revealed that the inhibitor-3-aminopyrrolidine scaffold exhibits high preferential affinity with GSK3*β*. While all inhibitors appear to sit in the ATP pocket of GSK3*β*, the most favorable is inhibitor 6 and the least probable is inhibitor 5.

3. Results and Discussion {#sec3}
=========================

In the present study, the analysis of 10 tau kinases implicated in AD has been performed to elucidate the conservation of the binding site and selectivity of the 7 inhibitors. Multiple sequence alignment, 3D structural alignment, catalytic active site overlap, and docking studies of inhibitors with GSK3*β* have been carried out to fingerprint the interactions with the key/gatekeeper residues in the ATPbinding pocket. The results highlight that tau protein kinases share common structural elements for the binding of the inhibitors and ATP. Comparatively, the inhibitor 3-aminopyrrolidine (inhibitor 6) exhibits high preferential affinity with GSK3*β*. Interestingly, the literature on AD indicates the overexpression and activity of GSK3*β* during pathogenesis of AD, and surprisingly, the PDB does not contain the structural details of GSK3*β* with this specific inhibitor. Our studies disclose that regions of the active site which found high conservation across tau kinases may form the determinants for binding to the ligand. Interactions of 7 inhibitors with the remaining 9 tau kinases in AD are also being explored.

4. Conclusions {#sec4}
==============

Our results indicate that the binding pocket of the 10 tau kinases is structurally conserved and offer a common feature of determinants with the 7 inhibitors investigated. Specific analysis with GSK3*β* reveals preferential binding to 3-aminopyrrolidine scaffold. This study highlights that suitable therapeutics can be successfully developed from the available chemical space, thus facilitating inhibitor design and off-target effects for AD.
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###### 

Details of 10 tau kinases used in the analysis.

  Sl. number   Protein name                                                                   UniProt ID   PDB ID   Number of residues   Ligand present in the PDB structure                                                                                    Nomenclature of inhibitors in the study
  ------------ ------------------------------------------------------------------------------ ------------ -------- -------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  \(1\)        Glycogen synthase kinase 3 beta (GSK3*β*)                                      P49841       1J1C     420                  Adenosine-5′-diphosphate                                                                                               ---
  \(2\)        Cyclin-dependent kinase 5 (CDK5)                                               Q00535       3O0G     292                  4-Amino-2-\[\[4-chlorophenyl\]amino\]-1,3-thiazol-5-yl\]\[3-nitrophenyl\]methanone                                     Inhibitor 1
  \(3\)        p38 delta kinase (p38)                                                         O15264       3COI     365                  No Ligand                                                                                                              ---
  \(4\)        Mitogen-activated protein kinase 1 (Erk1/2)                                    P28482       1TVO     360                  5-\[2-Phenylpyrazolo\[1,5-a\]pyridin-3-yl\]-1h-pyrazolo\[3,4-c\]pyridazin-3-amine \[Drug Bank ID DB07794\]             Inhibitor 2
  \(5\)        Mitogen-activated protein kinase 10 (JNK3)                                     P53779       2O0U     464                  N-{3-Cyano-6-\[3-\[1-piperidinyl\]propanoyl\]-4,5,6,7-tetrahydrothieno\[2,3-c\]pyridin-2-yl}1-naphthalenecarboxamide   Inhibitor 3
  \(6\)        Casein kinase 1 delta (CK1d)                                                   P48730       3UYT     415                  4-\[1-Cyclohexyl-4-\[4-fluorophenyl\]-1H-imidazol-5-yl\]pyrimidin-2-amine                                              Inhibitor 4
  \(7\)        Dual-specificity tyrosine-\[Y\]-phosphorylation-regulated kinase 1A (DYRK1A)   Q13627       3ANR     763                  7-Methoxy-1-methyl-9h-beta-carboline \[harmine complex\] \[Drug Bank ID DB07919\]                                      Inhibitor 5
  \(8\)        Protein kinase A (PKA)                                                         P17612       3MVJ     351                  \[3R\]-1-\[5-Methyl-7H-pyrrolo\[2,3-d\]pyrimidin-4-yl\]pyrrolidin-3-amine                                              Inhibitor-6 (3-aminopyrrolidine scaffold)
  \(9\)        Protein kinase B (PKB/AKT)                                                     P31749       3MV5     480                  \[3R\]-1-\[5-Methyl-7H-pyrrolo\[2,3-d\]pyrimidin-4-yl\]pyrrolidin-3-amine                                              Inhibitor-6 (3-aminopyrrolidine scaffold)
  \(10\)       Protein kinase C alpha (PKC)                                                   P17252       3IW4     672                  3-\[1H-Indol-3-yl\]-4-\[2-\[4-methylpiperazin-1-yl\]quinazolin-4-yl\]-1H-pyrrole-2,5-dione                             Inhibitor 7

###### 

Percentage identity, similarity, and RMSD values (for the overlapping number of atoms).

  -----------------------------------------------------------------------------------------------------------------------------------------------
           GSK3*β*        CDK5           P38            ERK1/2         JNK            CK1d           DYRK1A         AKT            PKA
  -------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  CDK5     ^\#^35.6%\     ---            ---            ---            ---            ---            ---            ---            ---
           ^@^66.0%\                                                                                                               
           \*1.25 (238)                                                                                                            

  P38      32.3%\         36.4%\         ---            ---            ---            ---            ---            ---            ---
           62.0%\         64.9%\                                                                                                   
           \*1.45 (221)   \*1.52 (202)                                                                                             

  ERK1/2   32.8%\         37.6%\         49.0%\         ---            ---            ---            ---            ---            ---
           64.5%\         68.0%\         77.4%\                                                                                    
           \*1.43 (252)   \*1.42 (233)   \*1.60 (277)                                                                              

  JNK      28.0%\         35.4%\         47.7%\         43.1%\         ---            ---            ---            ---            ---
           54.8%\         64.3%\         75.3%\         73.8%\                                                                     
           \*1.59 (238)   \*1.61 (228)   \*1.65 (265)   \*1.46 (287)                                                               

  CK1d     25.3%\         22.8%\         25.6%\         29.5%\         24.6%\         ---            ---            ---            ---
           49.6%\         48.1%\         54.0%\         50.4%\         50.8%\                                                      
           \*1.64 (205)   \*1.60 (200)   \*1.72 (167)   \*1.75 (195)   \*1.76 (188)                                                

  DYRK1A   28.4%\         30.4%\         29.1%\         28.3%\         28.9%\         24.5%\         ---            ---            ---
           53.2%\         7.5%\          53.6%\         57.1%\         52.3%\         51.8%\                                       
           \*1.29 (253)   \*1.34 (243)   \*1.52 (218)   \*1.39 (246)   \*1.72 (247)   \*1.57 (213)                                 

  AKT      27.0%\         25.4%\         26.1%\         22.8%\         26.3%\         25.8%\         26.0%\         ---            ---
           48.4%\         57.4%\         56.7%\         53.1%\         52.5%\         54.5%\         56.4%\                        
           \*1.55 (222)   \*1.47 (214)   \*1.61 (205)   \*1.48 (231)   \*1.64 (221)   \*1.68 (207)   \*1.36 (230)                  

  PKA      26.4%\         23.4%\         26.6%\         24.1%\         26.3%\         26.1%\         26.0%\         45.6%\         ---
           59.2%\         58.9%\         59.4%\         53.9%\         52.9%\         53.8%\         57.1%\         77.2%\         
           \*1.56 (213)   \*1.50 (207)   \*1.65 (183)   \*1.65 (214)   \*1.72 (194)   \*1.76 (207)   \*1.50 (219)   \*1.21 (292)   

  PKC      24.8%\         27.8%\         27.9%\         23.9%\         24.6%\         23.5%\         25.9%\         47.4%\         32.8%\
           51.8%\         61.9%\         56.4%\         56.2%\         50.8%\         55.8%\         56.7%\         79.2%\         60.3%\
           \*1.52 (223)   \*1.45 (214)   \*1.65 (203)   \*1.68 (228)   \*1.82 (221)   \*1.70 (208)   \*1.43 (224)   \*1.07 (285)   \*1.37 (279)
  -----------------------------------------------------------------------------------------------------------------------------------------------

^\#^Identity, ^@^similarity, and \*RMSD (total number of atoms involved).

###### 

Structures of 7 potential small molecule inhibitors and their relative binding affinities (IC~50~ and *K* ~*i*~) values.

  --
  --

###### 

RMSD values of ATP and the seven kinase inhibitors amongst each other.

                Inhibitor 1   Inhibitor 2   Inhibitor 3   Inhibitor 4   Inhibitor 5   Inhibitor 6   Inhibitor 7
  ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  Inhibitor 1   ---           ---           ---           ---           ---           ---           ---
  Inhibitor 2   0.57          ---           ---           ---           ---           ---           ---
  Inhibitor 3   0.46          0.32          ---           ---           ---           ---           ---
  Inhibitor 4   0.56          0.66          0.54          ---           ---           ---           ---
  Inhibitor 5   0.43          0.41          0.33          0.52          ---           ---           ---
  Inhibitor 6   0.51          0.39          0.46          0.49          0.49          ---           ---
  Inhibitor 7   0.53          0.54          0.41          0.54          0.41          0.55          ---
  ATP           0.37          0.64          0.58          0.54          0.51          0.67          0.48

###### 

Interaction of binding site residues amongst the 10 tau kinases with ATP.

  GSK3*β*                CDK5            P38              ERK1/2           JNK              CK1d            DYRK1A           AKT              PKA             PKC             ATP binding site conservation across the 10 kinases
  ---------------------- --------------- ---------------- ---------------- ---------------- --------------- ---------------- ---------------- --------------- --------------- -----------------------------------------------------
  ^\#^I 62 \*\[4.4\]     I10 \[5.70\]    V31 \[4.24\]     I 31 \[5.59\]    I 70 \[4.23\]    I 15-\[2.36\]   I 165-\[3.09\]   L156 \[4.34\]    L49 \[4.10\]    L345 \[4.70\]   I/V/L
  ^\#^G 63 \*\[5.4\]     G11 \[4.7\]     G32 \[3.97\]     G32 \[\>6\]      G71 \[4.31\]     G16 \[3.24\]    G166 \[5.12\]    G157 \[3.95\]    G50 \[4.88\]    G346 \[4.81\]   G-well conserved
  ^\#^N 64 \*\[5.24\]    ---             S33 \[3.93\]     E33 \[\>6\]      ---              ---             K167 \[4.60\]    K158-\[2.95\]    T51 \[2.76\]    K347 \[5.88\]   Not conserved
  ^\#^G 65 \*\[4.03\]    ---             G34 \[3.36\]     Y36 \[2.79\]     ---              ---             G168 \[5.72\]    G159 \[5.08\]    G52 \[3.90\]    G348 \[\>6\]    Not conserved
  ^\#^S 66 \*\[2.82\]    ---             A35 \[3.64\]     ---              ---              ---             S169 \[\>6\]     ---              S53 \[4.59\]    S349 \[5.81\]   Not conserved
  ^\#^F 67 \*\[3.21\]    ---             Y36 \[3.17\]     ---              ---              F20 \[5.54\]    F170 \[\>6\]     F161 \[5.54\]    F54 \[3.82\]    ---             Not conserved
  ^\#^V 70 \*\[5.9\]     V18-\[2.72\]    V39 \[2.89\]     V39 \[2.79\]     V78 \[\>6\]      I 23 \[5.07\]   V173 \[\>6\]     V164 \[4.93\]    V57 \[2.88\]    V353 \[4.80\]   V/I
  ^\#^A 83 \*\[5.46\]    A31 \[4.61\]    A52 \[4.93\]     A52 \[4.64\]     A91 \[5.99\]     A 36 \[5.42\]   A186 \[5.00\]    A177 \[4.90\]    A70 \[4.49\]    A366 \[4.51\]   A-well conserved
  ^\#^K 85 \*\[2.64\]    K33 \[4.28\]    K54-\[2.67\]     K54-\[2.93\]     K93 \[5.18\]     K38 \[3.23\]    K188 \[3.19\]    I179 \[5.23\]    K72-\[3.72\]    K368-\[2.31\]   K-well conserved
  ^\#^E 97 \*\[4.59\]    E51 \[\>6\]     E72 \[4.96\]     E71 \[3.71\]     E111 \[5.66\]    E52 \[3.78\]    E203 \[3.24\]    E198 \[4.93\]    E91 \[5.32\]    E387 \[3.45\]   E-well conserved
  ^\#^V 110 \*\[5.1\]    V64 \[\>6\]     I85 \[\>6\]      I84 \[\>6\]      I124 \[\>6\]     P66 \[\>6\]     V222 \[5.80\]    T211 \[4.13\]    V104 \[5.40\]   T401 \[3.29\]   V/I/P/T
  ^\#^L 132 \*\[5.7\]    F80 \[4.31\]    M107 \[5.06\]    Q105-\[2.29\]    M146-\[2.18\]    M82-\[2.40\]    F238 \[4.71\]    M227 \[4.36\]    M120 \[4.50\]   M417 \[3.24\]   F/Q/M
  ^\#^D 133 \*\[2.58\]   E81-\[2.86\]    P108-\[2.49\]    D106-\[2.96\]    E147 \[5.39\]    E-83-\[2.83\]   E239-\[2.54\]    E228-\[2.88\]    E121-\[2.52\]   E418-\[3.05\]   D/E-well conserved
  ^\#^Y 134 \*\[3.9\]    F82 \[5.08\]    F109 \[4.65\]    L107 \[3.03\]    L148 \[3.63\]    L84 \[4.73\]    M240 \[3.57\]    Y229 \[3.81\]    Y122 \[5.50\]   Y419 \[3.44\]   F/L/M/Y
  ^\#^V 135 \*\[3.05\]   C83-\[3.19\]    M110-\[3.13\]    M108-\[3.03\]    M149-\[2.51\]    L85-\[2.97\]    L241-\[2.84\]    A230-\[3.20\]    V123-\[2.69\]   V420-\[2.64\]   C/M/L/A/V
  ^\#^T 138 \*\[5.6\]    D86-\[2.74\]    D113-\[2.89\]    D111-\[2.77\]    N152-\[2.45\]    S88-\[2.91\]    N244 \[4.37\]    E 234-\[2.63\]   E127-\[3.01\]   D424-\[2.99\]   D/N/S/E
  ^\#^R 141 \*\[3.10\]   K89 \[5.45\]    K116 \[5.32\]    K 114 \[3.92\]   Q 155 \[4.03\]   D 91 \[4.42\]   D247 \[5.51\]    F237 \[4.76\]    S130 \[5.50\]   Y427 \[\>6\]    R/K/Q/D/F/S/Y
  ^\#^Q 185 \*\[2.98\]   Q130-\[2.66\]   G 154 \[4.71\]   S153-\[2.71\]    S193 \[4.42\]    D132 \[3.84\]   E291 \[4.66\]    E278-\[3.11\]    E170 \[2.30\]   D467-\[3.23\]   Q/G/S/D/E
  ^\#^N 186 \*\[3.45\]   N131 \[4.33\]   N155 \[\>6\]     N154 \[3.98\]    N194 \[4.09\]    N133 \[2.88\]   N292 \[3.39\]    N279 \[5.38\]    N171 \[3.22\]   N468 \[4.22\]   N-well conserved
  ^\#^L 188 \*\[5.8\]    L133 \[5.76\]   A157 \[5.79\]    L156 \[\>6\]     V196 \[\>6\]     L135 \[5.29\]   L294 \[\>6\]     M281 \[5.54\]    L173 \[5.88\]   M470 \[4.33\]   L/A/V/M
  ^\#^C 199 \*\[4.63\]   A143 \[5.93\]   L167 \[\>6\]     C166 \[4.09\]    L206 \[5.20\]    I148 \[6.06\]   V306 \[2.70\]    T291 \[3.83\]    T183 \[3.62\]   A480 \[4.27\]   C/A/L/I/V/T
  ^\#^D 200 \*\[4.84\]   N144 \[3.72\]   D168 \[5.04\]    D167 \[3.79\]    D207 \[4.19\]    D149 \[2.97\]   D307-\[2.72\]    D292 \[3.11\]    D184 \[3.96\]   D481-\[2.59\]   D-well conserved
                                                                                                                                                                              
  22                     16              19               16               15               18              18               21               22              18              Number of interacting residues with ATP within 6 Å

^\#^Indicates residue type and number; \*indicates distances in Angstroms.

###### 

Binding site residues of GSK3*β* interacting with 7 inhibitors when docked in the ATP Pocket.

  Residues in the ATP binding site of GSK3*β*                             ATP    Inhibitor 1   Inhibitor 2   Inhibitor 3   Inhibitor 4   Inhibitor 5   Inhibitor 6   Inhibitor 7   Number of interactions each residue has across inhibitors (within 6 Å)
  ----------------------------------------------------------------------- ------ ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------------------------------------------------------------------
  I 62                                                                    4.4    ---           3.62          2.35          4.09          3.98          2.90          2.84          6
  G 63                                                                    5.4    ---           ---           ---           ---           ---           4.50          3.20          3
  N 64                                                                    5.24   ---           ---           ---           ---           ---           ---           4.56          4
  G 65                                                                    4.03   ---           ---           ---           ---           ---           ---           ---           1
  S 66                                                                    2.82   ---           ---           ---           ---           ---           ---           ---           1
  F 67                                                                    3.21   ---           ---           ---           ---           ---           ---           ---           1
  V 70                                                                    5.9    4.09          ---           5.20          ---           ---           5.37          ---           4
  A 83                                                                    5.46   4.96          5.51          ---           5.80          ---           5.03          ---           5
  K 85                                                                    2.64   3.03          ---           3.21          5.02          ---           ---           2.84          5
  E 97                                                                    4.59   ---           ---           ---           ---           ---           ---           ---           1
  V 110                                                                   5.1    ---           3.35          ---           ---           ---           ---           ---           2
  L 132                                                                   5.7    ---           4.41          5.69          ---           ---           5.11          ---           4
  D 133                                                                   2.58   2.62          2.88          3.21          2.87          ---           3.03          ---           6
  Y 134                                                                   3.9    ---           ---           ---           2.77          ---           5.65          ---           3
  V 135                                                                   3.05   2.39          2.90          2.65          2.72          4.81          2.59          5.72          8
  T 138                                                                   5.6    ---           ---           ---           ---           ---           ---           ---           1
  R 141                                                                   3.12   4.91          2.17          ---           3.75          4.51          5.15          3.81          7
  Q 185                                                                   2.98   ---           ---           2.99          5.89          ---           2.94          2.90          5
  N 186                                                                   3.45   ---           ---           4.64          ---           ---           4.368         ---           3
  L 188                                                                   5.8    4.03          5.12          ---           ---           ---           ---           ---           3
  C 199                                                                   4.63   4.05          ---           ---           ---           ---           ---           ---           2
  D 200                                                                   4.84   2.70          4.57          3.45          ---           ---           ---           ---           4
                                                                                                                                                                                   
  Number of interacting residues across various inhibitors (within 6 Å)   22     9             9             9             8             3             11            7             ---

[^1]: Academic Editor: Jesús Avila
